Evofem Biosciences reported a decrease in net product sales to $4.5 million compared to $5.1 million in the prior year period. However, the operating loss improved to $2.4 million compared to an operating loss of $3.6 million in the third quarter of 2023.

Evofem Biosciences announced its Q2 2024 financial results, featuring a net product sales increase to $4.2 million compared to $2.5 million in the prior year period. The company also reported an improved operating loss of $1.4 million compared to $7.3 million in the same period last year. They acquired SOLOSEC and forged a commercial agreement for Phexxi in the Middle East.

Evofem Biosciences announced its Q3 2023 financial results, highlighting a net product sales of $5.1 million, a significant reduction in operating expenses, and a net income of $66.0 million, or $15.34 per basic share.

Evofem Biosciences reported a strong increase in net product sales for 2022, more than doubling compared to the previous year. The company also significantly reduced total operating expenses, exceeding its stated goal. However, they are still working towards achieving EBITDA break-even by the end of 2023.

Evofem Biosciences announced strong second quarter 2022 financial results, featuring a 42% increase in Phexxi net product sales compared to the previous quarter, alongside reduced operating expenses and an improved operating loss. The company also completed a registrational Phase 3 trial for Phexxi and anticipates top-line data in October 2022.

Evofem Biosciences reported a strong fourth quarter, driven by a 109% increase in net product sales compared to the previous quarter. The company also reduced its net cash burn rate and completed enrollment in a Phase 3 trial for Phexxi.

Evofem Biosciences reported Phexxi net product sales of $1.7 million for the third quarter of 2021. The company experienced a 29% increase in gross revenues compared to the second quarter of 2021, driven by ex-factory sales growth. Operating expenses increased by 5% to $45.1 million. The company expects to reduce operating expenses by approximately $50 million in 2022.

Evofem Biosciences reported a 68% increase in Phexxi net product sales, reaching $1.9 million, alongside a decrease in total operating expenses by 6%. The company's net loss attributable to common stockholders improved to $33.4 million, or $(0.27) per share.

Evofem Biosciences reported net product sales of $170,000 for the fourth quarter of 2020, their first full quarter of product sales after launching Phexxi. The company's "Get Phexxi" DTC campaign generated over 115 million views in its first two weeks, leading to increased consumer awareness.

Evofem Biosciences reported its first quarter of product sales, with net product sales of $0.3 million following the U.S. commercial launch of Phexxi. The company also initiated its Phase 3 EVOGUARD trial and secured a $25 million strategic investment.

Evofem Biosciences reported a net loss of $52.7 million for the second quarter of 2020. The company is preparing for the commercial launch of Phexxi in September 2020 and is on track to initiate a Phase 3 trial of EVO100 in Q4 2020. They ended the quarter with $123.6 million in unrestricted cash and short-term investments.

Evofem Biosciences reported a net loss of $19.1 million for the first quarter of 2020. The company is preparing for the potential launch of Phexxi in early September and had $10.3 million in unrestricted cash and short-term investments as of March 31, 2020.

Evofem Biosciences reported a decrease in total operating expenses and an improved net loss attributable to common stockholders for the fourth quarter of 2019. The company also announced the FDA granted conditional approval for the brand name Phexxi.